CIBC Private Wealth Group
ADAP

CIBC Private Wealth Group’s Adaptimmune Therapeutics ADAP Stock Holding History

CIBC Private Wealth Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,023
Closed -$682 – 3076
2025
Q1 		$682 Hold
3,023
– – ﹤0.01% 2860
2024
Q4 		$1.87K Hold
3,023
– – ﹤0.01% 2713
2024
Q3 		$2.87K Hold
3,023
– – ﹤0.01% 2741
2024
Q2 		$3.51K Sell
3,023
-73,698
-96% -$80.9K ﹤0.01% 2629
2024
Q1 		$113K Buy
+76,721
New +$92.6K ﹤0.01% 1346

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CIBC Private Wealth Group's ADAP Position: Q2 2025 in Review

CIBC Private Wealth Group sold out of Adaptimmune Therapeutics (ADAP) in Q2 2025, closing a stake of 3,023 shares — an estimated $682 sold.

CIBC Private Wealth Group first reported a position in ADAP in Q1 2024 and held it in 5 quarters. The position peaked at $113K in Q1 2024. 65 funds tracked by Wall St. Rank hold ADAP as of Q2 2025.

  • CIBC Private Wealth Group reported no remaining Adaptimmune Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CIBC Private Wealth Group sold 3,023 Adaptimmune Therapeutics shares in Q2 2025, an estimated $682.
  • CIBC Private Wealth Group first reported a position in Adaptimmune Therapeutics in Q1 2024 and held it in 5 quarters.
  • CIBC Private Wealth Group's Adaptimmune Therapeutics position peaked at $113K in Q1 2024.
  • 65 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2025.

Based on CIBC Private Wealth Group's 13F filing for Q2 2025, filed 12 Aug 2025.